Diabetes Mellitus is a physical condition associated with high blood sugar. It can have long-term detrimental effects on the blood vessels, heart, kidneys, eyes, and nerves. In 2015, diabetes was the 7th leading cause of death in America.
Despite the advances in diabetes treatment, it is still a major health problem. It can happen at any age, though, older patients suffer most from this disease. Furthermore, diabetes can attack a person from all racial and ethnic groups. However, people of certain races — including Hispanics, blacks, Asian-Americans and American Indians— are at higher risk.
Diabetes is caused by inadequate insulin activity. In some cases, the cells of the body are unable to respond to insulin properly, causing this malicious disease. More than 90% of all cases of diabetes are type 2, and the risk factors include obesity, family history, inactivity, and high blood pressure.
According to American Diabetes Association, 30.3 million Americans, i.e., 9.4% of the population, had diabetes in 2015. Out of them, nearly 1.25 million American children and adults had type 1 diabetes. In that year, 79,535 people died in America due to complications related to diabetes.
Market of Anti-Diabetic Drugs
In 2016, the size of anti-diabetics market was $43.6bn. With its worldwide market share of 5.4%, anti-diabetics maintained its dominant position in the market of prescription drugs and OTC. Novo Nordisk still dominates the anti-diabetics market, with its global market share of 29.7% in 2016. In this year, Novo Nordisk earned $12.9bn by selling anti-diabetic products, mainly Victoza, NovoRapid, and Tresiba. With its popular GLP-1 Trulicity, Eli Lilly is also maintaining its leading position. In 2016, the global sales of Trulicity reached $926M, with 2.1% of worldwide market share.
In addition, due to the entry of new competitors and biosimilar competition to its long-acting insulin Lantus, Sanofi slipped to third position, which earned $8.0bn globally in 2016. Another major player in this market is Boehringer Ingelheim, which had 3.9% of worldwide market share in 2016, with $1.6bn of sales.
Luca Dezzani is a Novartis employee. All the views, analysis, and perspectives are fully independent and belongs to the author only. They do not represent the views or opinions of Novartis or any other company or organization. IgeaHub is a pharmaceutical blog created and curated by Luca Dezzani. IgeaHub does not receive any funding or support from Novartis or any other pharmaceutical company.